Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092939 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL30042580 | 0.86 | RXFP1 (0.73) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL1013325 | 0.86 | RXFP1 (0.73) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL515007 | 0.85 | MAPT (0.62) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL2097862 | 0.85 | HDAC3 (0.59) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL9335041 | 0.84 | HPGD (0.62) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL514283 | 0.84 | MAPT (0.59) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL7565660 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL23447712 | 0.84 | MAPT (0.63) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL21138402 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2L3MBTL1MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-4386033-A | BOILING, CONDENSATION OF VAPORS, CIRCULATION; SEPARATION | BAYER AKTIENGESELLSCHAFT (DE) | 1983-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | SMN1; SMN2 3787/4885L3MBTL1 2575/4885MAPT 4299/4885 |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | SMN1; SMN2 4115/4885L3MBTL1 118/4885MAPT 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.